Features | Partner Sites | Information | LinkXpress
Sign In
Bio-Rad Diabetes Division
PURITAN MEDICAL
RANDOX LABORATORIES

Prostate Cancer Genetic Tests Predicts Prognosis

By Labmedica International staff writers
Posted on 21 Jan 2013
Diagnostic and prognostic genetic tests have been developed to better predict prostate cancer survival outcomes and distinguish clinically relevant cancers.

The diagnostic test distinguished patients with clinically relevant prostate cancer from normal prostate in men with elevated prostate-specific antigen (PSA) levels, and prognostic tests separate out men who died of prostate cancer versus those who lived.

Scientists at the Kimmel Cancer Center (Philadelphia, PA, USA) performed a retrospective analysis of over 350 patients using an oncogene-specific prostate cancer molecular signature, based on studies carried out in mice. They worked with three oncogenes previously associated with poorer outcomes in prostate cancer: avian myelocytomatosis viral oncogene homolog (c-Myc), Harvey rat sarcoma viral oncogene homolog (Ha-Ras), and sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (v-Src).

Canonical analysis was performed using the c-Myc-specific genes that were also found to be differentially expressed between tumor and normal samples in two human prostate datasets. The first canonical variable, resulting from this analysis, was used to discriminate tumor from normal samples in each human prostate dataset. The oncogene-specific prostate cancer molecular signatures were repeated and validated in distinct populations of patients as a prognostic and diagnostic test for human prostate cancer. The c-Myc gene copy number is increased in up to 30% of cases at the preneoplastic stage in patients with prostatic intraepithelial neoplasia. Specifically the tests identified men whose outcome was fatal on average after 30 months.

Richard G. Pestell, MD, PhD, the senior investigator of the study said, "This oncogene signature shows further value over current biomarkers of prediction and outcomes. Such a signature and cell line may also enable the identification of targets for therapies to better treat prostate cancer, which takes the lives of over 27,000 men a year. With this new oncogene-specific prostate cancer molecular signature, we have a valuable prognostic and diagnostic resource that could help change the way we manage and treat prostate cancer." The study was published online on November 30, 2012, in the journal Cancer Research.

Related Links:
Kimmel Cancer Center




DIASYS DIAGNOSTIC SYSTEMS
77 ELEKTRONIKA
KARL HECHT GMBH & CO KG

Channels

Hematology

view channel

Magnetic Resonance Improves Approach to Measuring Hemostasis Parameters

Two studies evaluating a magnetic resonance based detector for hemostasis measurements found its multiplex results to be rapid and accurate using lower blood volumes. At the International Society on Thrombosis and Hemostasis (ISTH) 2015 Congress (Toronto, Canada), T2 Biosystems, Inc. (Lexington, MA, USA) presented results... Read more

Lab Tech.

view channel
Image: Verigene System instrumentation consists of a Verigene Reader and one or multiple Verigene Processor SPs (Photo courtesy of Nanosphere).

Directed Molecular Diagnostic Tests Highlight Recent Microbiology Conference

The performance of a series of directed molecular diagnostic tests was confirmed by several studies presented at a recent microbiology conference. Nanosphere (Northbrook, IL, USA) manufactures tests... Read more

Industry News

view channel

QIAGEN Expands Diagnostics Menu in Partnership with Seegene

In a new collaboration, Seegene Inc. (Soul, Republic of Korea) will use its proprietary next-generation qPCR technology in developing new multiplex assays for the flagship platform of Qiagen NV (Venlo, Netherlands and Hilden, Germany). Seegene will develop a menu of multiplex assay panels for the modular QIAsymphony... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.